Zelluna ASA [ZLNA]: Annual Report 2024

02 Apr 2025 07:00 CEST

Oslo, Norway, 02 April, 2025 - Zelluna ASA, a company pioneering allogeneic 'off
the shelf' T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment
of cancer, announces that the Board of Directors of Zelluna ASA has approved the
Annual Report for 2024.

Please find a PDF version of the annual report, as well as the report in
European Single Electronic Format (ESEF), as attachments to this release. The
Annual Report is also available at the company's website: www.zelluna.com
(http://www.zelluna.com)

This information is subject to the disclosure requirements pursuant to Section
5-12 in the Norwegian Securities Trading Act.

For further information, please contact:

Anders Tuv, Chairman of the Board of Directors of Zelluna ASA
Email: at@radforsk.no (mailto:at@radforsk.no)
Phone: +47 982 06 826

Namir Hassan, CEO, Zelluna ASA
Email: namir.hassan@zelluna.com (mailto:namir.hassan@zelluna.com)
Phone: +44 7720 687608

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com (mailto:[%20hans.eid@zelluna.com])
Phone: +47 482 48632

More information:
Access the news on Oslo Bors NewsWeb site

642799_254900B4VALJZR9TL744-2024-12-31-0-en.zip
642799_Zelluna Annual Report 2024.pdf